Related Experiment Video
Updated: Jul 16, 2025

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives
Jun Zhou1,2, Zhuoying Ren1,2, Jie Xu1
1Center for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical Center, Ann Arbor 48109, MI, USA.
Abstract:
Gene editing nucleases (GENs), represented by CRISPR/Cas9, have become major tools in biomedical research and offer potential cures for many human diseases. Gene editing therapy (GETx) studies in animal models targeting genes such as proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein C3 (APOC3), angiopoietin Like 3 (ANGPTL3) and inducible degrader of the low-density lipoprotein receptor (IDOL) have demonstrated the benefits and advantages of GETx in managing atherosclerosis. Here we present our views on this brand new therapeutic option for cardiovascular diseases (CVD).
Related Concept Videos
What is Genetic Engineering?
CRISPR
Gene Therapy
Microorganisms in Medicine and Therapeutics
CRISPR/Cas9 Genome Editing

